Lv11
88 积分 2025-05-30 加入
What can real-world data teach us about treating patients with unresectable hepatocellular carcinoma?
2小时前
待确认
Efficacy and safety of pembrolizumab for the treatment of advanced biliary cancer: Results from the KEYNOTE‐158 and KEYNOTE‐028 studies
9天前
已完结
The Tumor Board: Is It Worth Saving?
16天前
已完结
HER2-Targeted Therapies: Unraveling Their Role in Biliary Tract Cancers
1个月前
已完结
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
1个月前
已关闭
Integrating Quality of Life and Survival in Systemic Therapy for Advanced Hepatocellular Carcinoma: A Network Meta-Analysis
1个月前
已完结
Emerging Targeted Therapies and Strategies to Overcome Resistance in Biliary Tract Cancers
2个月前
已完结
Comparison of atezolizumab plus bevacizumab and lenvatinib in terms of efficacy and safety as primary systemic chemotherapy for hepatocellular carcinoma
3个月前
已完结
Using ALBI score at the start of sorafenib treatment to predict regorafenib treatment candidates in patients with hepatocellular carcinoma
3个月前
已完结
Larotrectinib for Newly Diagnosed Infantile Fibrosarcoma and Other Pediatric NTRK Fusion–Positive Solid Tumors (Children's Oncology Group ADVL1823)
3个月前
已关闭
皖公网安备34019202002308
